Stockscreener 앱 받기
36.52
1.62%
-0.60
시간 외 거래:
36.54
0.02
+0.05%
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Exploring the Road Ahead: X-linked Hypophosphatemia Market - openPR.com
(RARE) Long Term Investment Analysis - news.stocktradersdaily.com
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com Canada
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia
FDA approves Ultragenyx's Mepsevii in mucopolysaccharidosis type VII enzyme disorder - FirstWord Pharma
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Ultragenyx (RARE) Q1 2025 Performance Shows Resilience - GuruFocus
Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com
How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com
Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq
Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN
William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus
William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com
William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com
Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus
Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan
Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN
Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus
(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com
1.11%
1.70%
자본화:
|
볼륨(24시간):